BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines.

co-founder and chief medical officer of BioNTech. "We must not forget that cancer is also a global health threat, even worse than the current pandemic," she added. Discover how AI is transforming ...

S eniors and people who are immunocompromised should get not just one but two COVID-19 shots this respiratory virus season.

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

The rare events — identified early in the pandemic — included a higher risk of heart-related inflammation from mRNA shots ...

The developers - Pfizer and BioNTech - described it as a "great ... a much-needed breakthrough to help bring an end to this global health crisis." Prof Ugur Sahin, one of the founders of BioNTech ...

Scientists at BioNTech’s laboratory in Mainz also ... Bishop said the team had worked with the Global Health Drug Discovery Institute to use LLMs to discover new molecules to treat tuberculosis ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of ... through a global license from OncoC4, and the firms hope that ...

Now, Pfizer and BioNTech are joining forces to try to grab ... which is at the same time more easily scalable to support global access," he added. Shingrix is a recombinant protein subunit-based ...

Antiviral Immunoglobulin Market. The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is ...

a critical factor to reach herd immunity and end this pandemic for the global population," Ugur Sahin, CEO and co-founder of BioNTech, was quoted as saying in the statement. The new results came a ...

BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million.